Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma

Anticancer Research

Volumn 33, Issue 9, 2013, Pages 3855-3860

  Coosemans, An ^a,c   Vanderstraeten, Anke ^a   Tuyaerts, Sandra ^a   Verschuere, Tina ^a   Moerman, Philippe ^b,c   Berneman, Zwi ^d   Vergote, Ignace ^a,c   Amant, Frédéric ^a,c   Van Gool, Stefaan W ^a,c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF IMAGING AND PATHOLOGY   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Carcinosarcoma; DC immunotherapy; Ovarian cancer; WT1

Indexed keywords

BEVACIZUMAB; CD137 ANTIGEN; DOXORUBICIN; GAMMA INTERFERON; GEMCITABINE; INTERLEUKIN 10; INTERLEUKIN 2; MESSENGER RNA; PACLITAXEL; TUMOR NECROSIS FACTOR ALPHA; WT1 PROTEIN;

ADULT; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOSARCOMA; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE COURSE; DRUG SAFETY; EX VIVO STUDY; FEASIBILITY STUDY; FEMALE; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; LYMPHOCYTE DIFFERENTIATION; MAJOR CLINICAL STUDY; OVARIAN CARCINOSARCOMA; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

CARCINOSARCOMA; DC IMMUNOTHERAPY; OVARIAN CANCER; WT1;

CARCINOSARCOMA; CYTOKINES; DENDRITIC CELLS; ELECTROPORATION; FEMALE; HUMANS; IMMUNOTHERAPY; MIDDLE AGED; OVARIAN NEOPLASMS; RNA, MESSENGER; SURVIVAL ANALYSIS; WT1 PROTEINS;

EID: 84885015878     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Del Carmen MG, Birrer M and Schorge JO: Carcinosarcoma of the ovary: A review of the literature. Gynecol Oncol 125: 271-277, 2012.
2. Rauh-Hain AJ, Grodwon WB, Rodriguez N, Goodman AK, Boruta D 2nd, Schorge JO, Horowitz NS and del Carmen MG: Carcinosarcoma of the ovary: A case-control study. Gynecol Oncol 121: 477-481, 2011.
3. Thigpen JT, Blessing JA, DeGeest K, Look KY and Homesley HD: Cisplatin as initial chemotherapy in ovarian carcinosarcoma: A Gynecologic Oncology Group study. Gynecol Oncol 93: 336-339, 2004.
4. Mano MS, Rosa DD, Azambuja E, Ismael G, Braga S, D'Hondt V, Piccart M and Awada A: Current management of ovarian carcinosarcoma. Int J Gynecol Cancer 17: 316-324, 2007.
5. Vergote I, Amant F, Kristensen G, Ehlen T, Reed NS and Casado A: Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. Eur J Cancer 47: S88-92, 2011.
6. Yamamoto S, Tsuda H, Kita T, Maekawa K, Fujii K, Kudoh K, Furuya K, Tamai S, Inazawa J and Matsubara O: Clinicopathological significance of WT1 expression in ovarian cancer: A possible accelerator of tumor progression in serous adenocarcinoma. Virchows Arch 451: 27-35, 2007.
7. Yang L, Han Y, Suarez Saiz F and Minden MD: A tumor suppressor and oncogene: The WT1 story. Leukemia 21: 868-876, 2007.
8. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM and Matrisian LM: The prioritization of cancer antigens: A National Cancer Institute pilot project for the acceleration of translational research. Clin Cancer Res 15: 5323-5337, 2009.
9. Ohno S, Kyo S, Moyojo S, Dohi S, Ishizaki J, Miyamoto K, Morita S, Sakamoto J, Enomoto T, Kimura T, Oka Y, Tsuboi A, Sugiyama H and Inoue M: Wilms' tumor 1 (WT1) peptide immunotherapy for gynaecological malignancy. Anticancer Res 29: 4779-4784, 2009.
10. Miyatake T, Ueda Y, Morimoto A, Enomoto T, Nishida S, Shirakata T, Oka Y, Tsuboi A, Oji Y, Hosen N, Nakatsuka SI, Morita S, Sakamoto J, Sugiyama H and Kimura T: WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial. J Cancer Res Clin Oncol 139: 457-463, 2013.
11. Franko A, Magliocco AM, Duan Q and Duggan MA: WT1 immunoprofiling and comparison of malignant Mullerian mixed tumors of the female genital tract. Int J Gynecol Pathol 29: 452-458, 2010.
12. Cathro HP and Stoler MH: The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors. Hum Pathol 36: 195-201, 2005.
13. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, Sciot R, Wilms G, Demaerel P, Warmuth-Metz M, Soerensen N, Wolff JE, Wagner S, Kaempgen E and Van Gool SW: Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14: 3098-3104, 2008.
14. Coosemans A, Wölfl M, Berneman ZN, Van Tendeloo V, Vergote I, Amant F and Van Gool SW: Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma. Anticancer Res 30: 3699-3704, 2010.
15. Hernando JJ, Park TW, Fischer HP, Zivanovic O, Braun M, Pölcher M, Grünn U, Leutner C, Pötzsch B and Kuhn W: Vaccination with dendritic cells transfected witg mRNAendcoded folate-receptor-alpha for relapsed metastatic ovarian cancer. Lancet Oncol 8: 451-454, 2007.
16. Erdmann M, Dorrie J, Schaft N, Strasser E, Hendelmeier M, Kämpgen E, Schuler G and Schuler-Thurner B: Effective clinicalscale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection. J Immunother 30: 663-674, 2007.
17. Michiels A, Tuyaerts S, Bonehill A, Corthals J, Breckpot K, Heirman C, Van Meirvenne S, Dullaers M, Allard S, Brasseur F, van der Bruggen P and Thielemans K: Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther 12: 772-782, 2005.
18. Oka Y, Tsuboi A, Oji Y, Kawase I and Sugiyama H: WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol 20: 211-220, 2008.
19. De Vleeschouwer S, Spencer Lopes I, Ceuppens J and Van Gool SW: Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells. J Neurooncol 84: 131-140, 2007.
20. Lotem M, Shiloni E, Pappo I, Drize O, Hamburger T, Weitzen R, Isacson R, Kaduri L, Merims S, Frankenburg S and Peretz T: Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. Br J Cancer 90: 773-780, 2004.
21. Terada KY, Johnson TL, Hopkins M and Roberts JA: Clinicopathologic features of ovarian mixed mesodermal tumors and carcinosarcomas. Gynecol Oncol 32: 228-232, 1989.
22. Prendiville J, Murphy D, Renninson J, Buckley H and Crowther D: Carcinosarcoma of the ovary treated over a 10-year period at the Christie Hospital. Int J Gynecol Cancer 4: 200-205, 1994.
23. Chang J, Sharpe JC, A'Hern RP, Fisher C, Blake P, Shepherd J and Gore ME: Carcinosarcoma of the ovary: Incidence, prognosis, treatment and survival of patients. Ann Oncol 6: 755-758, 1995.
24. Sit AS, Price FV, Kelley JL, Comerci JT, Kunschner AJ, Kanbour-Shakir A and Edwards RP: Chemotherapy for malignant mixed mullerian tumors of the ovary. Gynecol Oncol 79: 196-200, 2000.
25. Duska LR, Garrett A, Eltabakh GH, Oliva E, Penson R and Fuller AF: Paclitaxel and platinum chemotherapy for malignant mixed Mullerian tumors of the ovary. Gynecol Oncol 85: 459-463, 2002.
26. Harris MA, Delap LM, Sengupta PS, Wilkinson PM, Welch RS, Swindell R, Shanks JH, Wilson G, Slade RJ, Reynolds K and Jayson GC: Carcinosarcoma of the ovary. Br J Cancer 88: 654-657, 2003.
27. Inthasorn P, Beale P, Dalrymple C and Carter J: Malignant mixed mulleriantumour of the ovary: Prognostic factor and response of adjuvant platinum-based chemotherapy. Aust NZ J Obstet Gynaecol 43: 61-64, 2003.
28. Brown E, Stewart M, Rye T, Al-Nafussi A, Williams AR, Bradburn M, Smyth J and Gabra H: Carcinosarcoma of the ovary: 19 Years of prospective data from a single center. Cancer 100: 2148-2153, 2004.
29. Mok JE, Kim YM, Jung MH, Kim KR, Kim DY, Kim JH, Kim YT and Nam JH: Malignant mixed mullerina tumors of the ovary: Experience with cytoreductive surgery and platinum-based combination chemotherapy. Int J Gynecol Cancer 16: 101-105, 2006.
30. Crotzer DR, Wolf JK, Gano JB, Gershenson DM and Levenback C: A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary. Gynecol Oncol 105: 399-403, 2007.
31. Leiser AL, Chi DS, Ishill NM and Tew WP: Carcinosarcoma of the ovary treated with platinum and taxane: The Memorial-Sloan Kettering Cancer Center experience. Gynecol Oncol 105: 657-661, 2007.
32. Cicin I, Saip P, Eralp Y, Selam M, Topuz S, Ozluk Y, Aydin Y and Topuz E: Ovarian carcinosarcomas: Clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum. Gynecol Oncol 108: 136-140, 2008.
33. Shurin GV, Tourkova IL, Kaneno R and Shurin MR: Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol 83: 137-144, 2009.
34. Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI and Jaffee EM: Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factorsecreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61: 3689-3697, 2001.
35. Kaneno R, Shurin GV, Tourkova IL and Shurin MR: Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J Transl Med 7: 58, 2009.
36. Zhang L, Dermawan K, Jin M, Liu R, Zheng H, XuL, Zhang Y, Cai Y, Chu Y and Xiong S: Differential impairment of regulatory T-cells rather than effector T-cell by paclitaxel-based chemotherapy. Clin Immunol 129: 219-229, 2008.
37. Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, Bepler G, Simon G, Janssen W, Lee JH, Menander K, Chada S and Gabrilovich DI: Combination of p53 cancer vaccine with chemotherapy in patients with extensive-stage small cell lung cancer. Clin Cancer Res 12: 878-887, 2006.
38. Suzuki E, Kapoor V, Jassar AS, Kaiser LR and Albelda SM: Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11: 6713-6721, 2005.
39. Soeda A, Morita-Hoshi Y, Makiyama H, Morizane C, Ueno H, Ikeda M, Okusaka T, Yamagata S, Takahashi N, Hyodo I, Takaue Y and Heike Y: Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer. Jpn J Clin Oncol 39: 797-806, 2009.